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Abstract
Aim: To evaluate the salivary levels of myeloid-related markers in relation to peri-
odontal disease and their potential screening capability, as well as the effects of peri-
odontal treatment on these markers in periodontitis patients.
Materials and methods: Participants with a healthy periodontium (n = 60) and with
gingivitis (n = 63) and periodontitis (n = 72) were recruited. Periodontitis patients
received non-surgical treatment and were re-examined after 3 and 6 months.
Unstimulated saliva was collected at baseline and at 1, 3, and 6 months after therapy
for the periodontitis patients. Levels of colony-stimulating factor-1 (CSF-1),
interleukin-34 (IL-34), S100A8/A9, S100A12, hepatocyte growth factor (HGF), IL-1β,
and matrix metalloproteinase-8 (MMP-8) were analysed by immunoassays.
Results: CSF-1, S100A8/A9, S100A12, IL-1β, MMP-8, and HGF were significantly
elevated in saliva from periodontitis and gingivitis patients in comparison to healthy
individuals, whereas IL-34 was significantly lower in periodontitis compared to both
healthy individuals and gingivitis patients. IL-34 increased significantly 3 months after
treatment, while IL-1β and MMP-8 decreased 1 month after therapy. Additionally,
periodontitis patients clustered in high and low levels of S100A8/A9, whereby those
with high levels had more bleeding, deeper pockets, and higher S100A12.
Conclusions: Salivary levels of myeloid-related markers are altered in periodontitis
and are partially modulated by periodontal treatment. Measuring S100A8/A9 in
saliva may identify distinct groups of periodontitis patients.
K E YWORD S
myeloid cells, periodontal disease, saliva
Clinical Relevance
Scientific rationale for study: Myeloid cells are pivotal to the inflammatory process in periodonti-
tis. Thus, measuring molecules that reflect their functions in saliva has the potential to improve
screening and monitoring of periodontal inflammation.
Principal findings: Periodontitis patients showed altered levels of several myeloid-related markers
in saliva, and periodontitis treatment led to a significant increase in IL-34 and a reduction in IL-
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1β and MMP-8. S100A8/A9 levels in saliva identified two clusters of periodontitis patients with
differences in clinical and inflammatory parameters.
Practical implications: Measuring myeloid-related markers in saliva can be useful to assess peri-
odontal diseases. Evaluation of S100A8/A9 in saliva can inform identification of distinct groups
of periodontitis patients, potentially helping patient monitoring and treatment.
1 | INTRODUCTION
Periodontitis is a highly prevalent chronic disease, which is character-
ized by a microbiota-induced inflammation of the tooth-supporting
tissues and may eventually lead to tooth loss and contribute to the
systemic inflammatory burden. Immune cells infiltrate the periodontal
tissues and produce high concentrations of cytokines and proteolytic
enzymes such as matrix metalloproteinases (MMPs), which mediate
tissue damage leading to loss of function and clinical disease
(Preshaw & Taylor, 2011). Among the immune cells, myeloid cells play
a significant role in the pathogenesis of periodontitis, where they pro-
duce enzymes that undermine the integrity of the oral mucosa
(Bjornfot Holmstrom et al., 2017) and mediate alveolar bone resorp-
tion (Lam et al., 2014). Therefore, molecules reflecting myeloid cell
functions are potential biomarkers for the screening of periodontitis
and in the assessment of response to therapy.
Colony-stimulating factor-1 (CSF-1) and interleukin-34 (IL-34) are
growth factors regulating the survival, proliferation, and differentia-
tion of mononuclear phagocytes, which are synthesized by different
cell types (Pixley & Stanley, 2004), including gingival fibroblasts
(Bostrom & Lundberg, 2013; Clark et al., 2020). Both CSF-1 and IL-34
regulate the differentiation of mononuclear phagocytes to osteoclasts
in concert with the receptor activator of nuclear factor kappa-B ligand
(Pixley & Stanley, 2004; Bostrom & Lundberg, 2013). Blockade of the
CSF-1 receptor, which is shared by CSF-1 and IL-34, has been shown
to reduce alveolar bone loss in a periodontitis mouse model, highlight-
ing their role in periodontal pathology (Kimura et al., 2014). Addition-
ally, our group has reported dysregulated levels of CSF-1 and IL-34 in
saliva from patients with periodontitis (Lira-Junior, Akerman,
et al., 2017; Martinez et al., 2017) as well as increased expression of
CSF-1 in periodontitis-affected gingival tissue (Clark et al., 2020).
S100A8/A9, also known as calprotectin, and S100A12 are mem-
bers of the S100 calcium-binding family of proteins, which are pre-
dominantly expressed by myeloid cells, although they are also
inducible in other cell types (Perera et al., 2010). They function as
danger signals to activate both immune and endothelial cells (Foell
et al., 2007; Perera et al., 2010). S100A8/A9 and S100A12 are over-
expressed at sites of inflammation in chronic inflammatory diseases
(Foell et al., 2007), including periodontitis (Kido et al., 1999;
Lira-Junior et al., 2020). Furthermore, these proteins are increased in
saliva from periodontitis patients and could potentially be used as bio-
markers of periodontitis (Haririan et al., 2016; Holmstrom et al., 2019;
Lira-Junior et al., 2020). However, the assessment of these myeloid-
related proteins in saliva to monitor periodontal inflammation longitu-
dinally needs investigation, as well as their relationship to more
well-established markers of periodontal inflammation, such as hepato-
cyte growth factor (HGF), IL-1β, and MMP-8 (Jaedicke et al., 2016).
Therefore, we set out to investigate the levels of myeloid-related
markers in saliva in relation to periodontal disease and their potential
to screen periodontitis. Furthermore, we aimed to evaluate the effects
of non-surgical periodontal treatment on the salivary levels of these
markers in individuals with periodontitis. These markers might be use-
ful to screen periodontitis in settings where a clinical examination is
not feasible and to stratify periodontitis patients with potential impli-
cations for therapy.
2 | MATERIALS AND METHODS
2.1 | Study participants
This study included 195 participants, among which 60 were periodon-
tally healthy, 63 had gingivitis, and 72 had periodontitis. Individuals were
recruited at the Newcastle upon Tyne Dental Hospital, following ethical
approval (UK National Research Ethics Service North East Newcastle
and North Tyneside 1 committee, ref: 12/NE/0396). All participants
provided written informed consent and the study procedures were in
accordance with the principles outlined in the Declaration of Helsinki.
The included participants were adults, between 18 and 65 years of
age, non-smokers, and with a minimum of 20 natural teeth excluding
third molars. Healthy participants had no sites with inter-proximal
attachment loss, probing pocket depth (PPD) of ≤3 mm in all sites,
bleeding on probing (BOP) ≤ 10%, and had <10% of sites with modified
gingival index (mGI) ≥ 2; gingivitis participants had no sites with inter-
proximal attachment loss or PPD > 4 mm, and had BOP ≥10% and
>30% of the sites with mGI ≥3; patients with periodontitis had inter-
proximal PPD ≥5 mm at ≥8 teeth and BOP ≥30%. Participants with peri-
odontitis were diagnosed with moderate to severe periodontitis
according to the classification system in use at the time
(Armitage, 1999), corresponding to periodontitis stage 3 or 4, and grade
B according to the new classification (Tonetti et al., 2018). Participants
were excluded if they had infectious or systemic diseases, were under-
going treatment with antibiotics or immunosuppressants, were pregnant,
or had smoked cigarettes within the last 2 years (Taylor et al., 2019).
2.2 | Periodontal examination and treatment
A full-mouth periodontal examination was performed by one of two
calibrated clinical examiners who examined the same participants over
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the course of the study, including BOP, PPDs, and clinical attachment
loss (CAL) at six sites per tooth with a UNC-15 periodontal probe.
mGI was also recorded (Lobene et al., 1986). Periodontal inflamed sur-
face area and periodontal epithelial surface area were calculated as
described previously (Nesse et al., 2008). Body mass index (BMI) was
also calculated. Periodontitis patients received non-surgical periodon-
tal therapy, which comprised root surface debridement and oral
hygiene instruction. Patients were re-examined 3 and 6 months after
therapy and provided with appropriate prophylaxis and oral hygiene
instruction according to clinical need. A total of 65 patients returned
to all follow-up visits.
2.3 | Saliva collection and biomarkers analysis
Unstimulated saliva samples were collected by expectoration into a
plastic tube and centrifuged at 1500g for 15 min at 4C. Aliquots were
stored at 80C until analysis. Saliva samples were collected at baseline
from all participants, and at 1, 3, and 6 months after therapy for peri-
odontitis patients. CSF-1, IL-34, S100A8/A9, S100A12, HGF, IL-1β, and
MMP-8 levels in saliva were measured by ELISA according to the manu-
facturer's instructions (R&D Systems, Minneapolis, MN). Apart from
S100A proteins, all other assays were Quantikine assays. The assays
had been previously validated for saliva in our respective labs (Jaedicke
et al., 2012; Martinez et al., 2017; Holmstrom et al., 2019). Readings
were taken using a microplate spectrophotometer (SpectraMAX
340, Sunnyvale, CA) at 450 nm with wavelength correction set to
540 nm to subtract background. Data regarding MMP-8 and IL-1β
levels have been partially reported previously (Taylor et al., 2019).
Saliva samples were randomized and blindly analysed. The code
key and the clinical status were revealed only after the laboratory analy-
sis was completed. IL-34 was detected in 86% of the samples, whereas
the other markers were detected in >95% of the samples. Samples
below the detection limit were set as half of the lowest detected value.
The sensitivity for each assay used in the study was as follows: CSF-1:
11.2 pg/ml; S100A8/A9: 20.4 pg/ml; S100A12: 7.8 pg/ml; IL-34:
3.06 pg/ml; HGF: 24.1 pg/ml; IL-1β: 1 pg/ml; and MMP-8: 0.058 ng/ml.
2.4 | Statistical analysis
Data analyses were performed using Statistical Package for Social
Sciences, version 25 (SPSS, IBM Corporation, Armonk, NY) and
GraphPad Prism 8 (GraphPad Software Inc., La Jolla, CA). Differences
among the groups were calculated by Mann–Whitney, Kruskal–Wallis
(with Dunn–Bonferroni post hoc), or Chi-square tests whenever
appropriate. Intra-group differences after treatment were determined
by the Friedman test with Dunn–Bonferroni post hoc test. Spearman's
rank coefficient was used to assess the correlations between bio-
markers levels in saliva and clinical parameters. The diagnostic capabil-
ity of each marker was evaluated by calculating the areas under the
curve of receiver-operating characteristics (AUC-ROC), sensitivity and
specificity. Statistical significance was set at a p-value ≤ .05.
3 | RESULTS
3.1 | Clinical characteristics of the study
participants
This study enrolled 60 periodontally healthy participants and 63 gingi-
vitis and 72 periodontitis patients. The clinical characteristics of the
three study groups are presented in Table 1. Periodontitis patients
were significantly older than both healthy and gingivitis participants
(p < .01), while no significant difference was seen between healthy
and gingivitis subjects. Periodontitis patients were also more fre-
quently male and former smokers (p = .007 and p < .001, respec-
tively). All periodontal parameters were significantly worse in
periodontitis patients than in both healthy and gingivitis participants.
With the exception of the number of teeth, gingivitis patients also
showed worse periodontal parameters than healthy subjects.
3.2 | Salivary levels of myeloid-related markers
in periodontal disease
We then investigated the levels of several myeloid-related markers in
saliva and their relation to periodontal parameters and to each other.
Salivary levels of CSF-1, S100A8/A9, S100A12, IL-1β, MMP-8, and
HGF were significantly elevated in both periodontitis and gingivitis
groups compared to control groups (Figure 1a–g). Additionally,
S100A8/A9, IL-1β, MMP-8, and HGF levels in saliva were significantly
increased in periodontitis in comparison with gingivitis. On the other
hand, salivary levels of IL-34 were significantly lower in the periodon-
titis group compared to both healthy and gingivitis groups (Figure 1b).
While CSF-1 was increased in disease, IL-34 was increased in health.
As both factors signal through the same receptor, CSF-1R, we looked
at the ratio between CSF-1 and IL-34 and found it was significantly
higher in periodontitis in comparison with both healthy and gingivitis
(p < .001 and p = .001, respectively; Figure S1a). Levels of CSF-1,
S100A8/A9, S100A12, IL-1β, MMP-8, and HGF showed significant
positive correlations with all periodontal parameters. IL-34 levels cor-
related negatively with the percentage of PPD ≥5 mm (Figure 1h).
Overall, there was no difference in any of the markers between men
and women (data not shown).
We analysed the diagnostic performance of these markers to dis-
tinguish between periodontitis and health and gingivitis alone, as well
as between periodontitis and non-periodontitis. Apart from IL-34, all
markers showed good ability to discriminate between periodontitis
and health (AUC > 0.75; Figure S2a). All markers also showed distinct
ability to differentiate between periodontitis and gingivitis with AUC
ranging from 0.615 to 0.770, with MMP-8 (AUC 0.759, 95% confi-
dence interval [CI] 0.68–0.84) and HGF (AUC 0.770, 95% CI 0.69–0.85)
displaying the highest values (Figure S2b). Regarding the ability to distin-
guish between periodontitis and non-periodontitis patients, MMP-8 and
HGF displayed the highest areas, with AUC of, respectively, 0.834 and
0.838 (95% CI 0.78–0.89; Figure S2c), while the AUC for the other
markers were as follows: CSF-1 (0.687, 95% CI 0.61–0.76); IL-34 (0.670,
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95% CI 0.59–0.75); S100A8/A9 (0.738, 95% CI 0.66–0.81); S100A12
(0.693, 95% CI 0.62–0.77); and IL-1β (0.783, 95% CI 0.72–0.85). The
sensitivity and specificity of each marker to discriminate periodontitis
from non-periodontitis are presented in Table S1.
3.3 | Effects of periodontal therapy on clinical
and salivary parameters
Next, we assessed the effects of periodontal therapy on periodontal
parameters and salivary markers. Periodontitis patients received
non-surgical periodontal treatment and were reassessed at 3 and
6 months after therapy. Out of the 72 periodontitis patients who
started the study, 65 completed it. All periodontal parameters
improved significantly 3 and 6 months after treatment in comparison
with the baseline (p < .001). No further improvement was seen at
6 months compared with 3 months (Table 2). At the end of the
follow-up, average reductions of 37.8% and 0.9 mm were seen in
mean BOP and PPD values, respectively, whereas the mean CAL
improved by 0.8 mm.
Considering the salivary markers, the levels of CSF-1 and HGF
did not change significantly after treatment (p = .067 and p = .089,
respectively; Figure 2a,g). IL-34 increased significantly 3 months after
treatment compared to the baseline (p = .042; Figure 2b). No signifi-
cant change was found in the levels of S100A8/A9 and S100A12
after non-surgical therapy (Figure 2c,d). On the contrary, IL-1β and
MMP-8 levels decreased significantly 1 month after therapy in com-
parison with the baseline (p = .001 and p = .010; Figure 2e,f).
Additionally, lowered level of IL-1β was seen 3 months after treat-
ment, but this did not reach statistical significance (p = .075). The
CSF-1/IL-34 ratio decreased significantly 3 months after treatment in
comparison with baseline (p = .002; Figure S1b).
3.4 | Salivary levels of S100A8/A9 stratifies
periodontitis patients
We observed two distinct clusters of periodontitis patients according
to their levels of S100A8/A9 in saliva at baseline (Figure 3a). One
cluster containing 34 patients presented low levels of S100A8/A9
(3080.2 ± 2453.5 ng/ml, “low” group). The second cluster, with
38 patients, presented on average 13 times higher S100A8/A9 in
saliva (40262.5 ± 22662.5 ng/ml, “high” group; p < .001). Patients
with high levels of S100A8/A9 were slightly younger than
patients with low levels (44.2 ± 8.3 vs. 48.6 ± 7.0; p = .043). They also
had more teeth, higher BOP, deeper pockets, and greater epithelial
and inflamed surface areas (p < .05; Table 3). Additionally, patients
with high levels of S100A8/A9 also had higher levels of S100A12
(p < .001; Figure 3d). No significant difference was found between
the groups in the levels of the other markers (Figure 3; Figure S1c).
Moreover, patients in the “high” group showed higher BOP, deeper
pockets, and greater epithelial and inflamed surface areas 3 months
after treatment. At the end of follow-up, patients in the “high” group
had higher gingival index scores and greater epithelial surface area
than the "low" group (p < .05; Table 3).
Regarding longitudinal changes in the levels of biomarkers, a dis-
tinct response pattern to therapy was observed in the groups.
S100A8/A9 levels increased significantly 3 and 6 months after treat-
ment in the “low” group (p = .031 and p = .004, respectively), while a
significant decrease was found 1 month after treatment in the “high”
TABLE 1 Clinical characteristics of
the study groups at baseline
Healthy (n = 60) Gingivitis (n = 63) Periodontitis (n = 72) p-Value
Age (years) 35.7 (±12.5) 38.2 (±11.5) 46.3 (±8.0)a,b <.001
Gender (M/F) 17/43 20/43 38/34 .007
Smoking (no/former) 54/6 54/9 44/28 <.001
BMI (kg/m2) 24.6 (±5.7) 26.2 (±5.4) 27.0 (±5.7)a .007
No. of teeth 26.8 (±1.5) 26.6 (±1.8) 26.0 (±1.9)a .023
Mean mGI 0.3 (±0.2) 2.4 (±0.3)a 2.8 (±0.4)a,b <.001
BOP (%) 2.7 (±3.0) 28.0 (±11.7)a 55.1 (±17.5)a,b <.001
Mean PPD (mm) 1.7 (±0.4) 2.1 (±0.3)a 3.8 (±0.8)a,b <.001
Mean CAL (mm) — — 4.5 (±0.9) —
PPD ≥ 5 mm (%) — — 33.2 (±15.9) —
PESA 849.7 (±183.6) 1040.6 (±206.9)a 2188.5 (±565.7)a,b <.001
PISA 30.3 (±34.9) 311.8 (±148.7)a 1394.7 (±660.3)a,b <.001
Note: Continuous variables are presented as the mean±standard deviation. Categorical variables are
presented as natural frequencies. p-Values were computed by Kruskal–Wallis (with Dunn–Bonferroni
post hoc) or Chi-square tests.
Abbreviations: BMI, body mass index; BOP, bleeding on probing; CAL, clinical attachment loss; mGI,
modified gingival index; PESA, periodontal epithelial surface area; PISA, periodontal inflamed surface
area; PPD, probing pocket depth.
aSignificant difference in comparison with healthy.
bSignificant difference in comparison with gingivitis.
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F IGURE 1 Salivary levels of myeloid-related markers in relation to periodontal disease and their correlations to clinical parameters. Salivary
levels of (a) Colony-stimulating factor-1 (CSF-1), (b) interleukin (IL)-34, (c) S100A8/A9, (d) S100A12, (e) hepatocyte growth factor (HGF), (f) IL-1β,
and (g) matrix metalloproteinase (MMP)-8 in healthy (n = 60) and gingivitis (n = 63) and periodontitis patients (n = 72). (h) Correlation heat map
of salivary markers and periodontal parameters. Spearman correlation was used. Groups were compared using Kruskal–Wallis tests with Dunn's
post hoc test. *p < .05, **p < .001. BOP, bleeding on probing; CAL, clinical attachment loss; MGI, mean gingival index; PESA, periodontal epithelial
surface area; PISA, periodontal inflamed surface area; PPD, probing depth [Colour figure can be viewed at wileyonlinelibrary.com]
TABLE 2 Clinical parameters of
participants with periodontitis at baseline
(M0) and 3 (M3) and 6 (M6) months post-
treatment
M0 (n = 72) M3 (n = 67) M6 (n = 67) p-Value
No. of teeth 26.0 (±1.9) 25.9 (±2.0) 25.9 (±2.0) .202
Mean mGI 2.8 (±0.4) 1.3 (±0.6)a 1.2 (±0.7)a <.001
BOP (%) 55.1 (±17.5) 18.7 (±15.3)a 17.3 (±12.9)a <.001
Mean PPD (mm) 3.8 (±0.8) 2.9 (±0.7)a 2.9 (±0.7)a <.001
Mean CAL (mm) 4.5 (±0.9) 3.7 (±0.9)a 3.7 (±0.9)a <.001
PPD ≥ 5 mm (%) 33.2 (±15.9) 14.8 (±12.9)a 14.7 (±12.4)a <.001
PESA 2188.5 (±565.7) 1584.7 (±482.4)a 1571.4 (±509.1)a <.001
PISA 1394.7 (±660.3) 400.8 (±433.6)a 377.4 (±411.7)a <.001
Note: Continuous variables are presented as mean±standard deviation. p-Values were computed by
Friedman tests with Dunn–Bonferroni post hoc test.
Abbreviations: BOP, bleeding on probing; CAL, clinical attachment loss; mGI, modified gingival index;
PESA, periodontal epithelial surface area; PISA, periodontal inflamed surface area; PPD, probing depth.
aSignificant difference in comparison with M0.
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group in comparison with the baseline (p = .034; Figure 3h). There
was no significant decrease at 6 months in the “high” group
(p = .060). S100A8/A9 levels remained significantly higher in the
“high” group than in the “low” group at 1 and 3 months after therapy
(p < .001 for both). IL-1β levels decreased significantly 1 and 3 months
after treatment compared to baseline in the “low” group (p = .001
and p = .026, respectively; Figure 3l). Similarly, MMP-8 and HGF
decreased significantly 1 month after treatment compared to baseline
in the “low” group (p = .001 and p = .022, respectively; Figure 3m,n).
Despite the lack of statistical significance, it is also interesting to note
some suggestion of patterns of change, such as lower MMP-8 levels
in the “low” group (p = .066; Figure 3m) and decreased CSF-1/IL-34
ratio in both “low” and “high” groups 3 months after therapy
(p = .063 and p = .096, respectively; Figure S1d), as well as an
increase in IL-34 levels in the “high” group (p = .077; Figure 3j), all of
which warrant further investigation in larger cohorts.
4 | DISCUSSION
The use of saliva for screening and monitoring diseases is constantly
evolving. Its use in periodontal disease has the potential to transform
periodontal care and provide information on early disease detection,
risk stratification, and response to therapy. In that regard, identifica-
tion and thorough investigation of markers related to pathogenic pro-
cesses are of utmost relevance. Myeloid cells play a significant role in
the inflammation-driven tissue destruction in periodontitis (Lam
et al., 2014; Bjornfot Holmstrom et al., 2017). Therefore, markers
reflecting their functions are putative candidates to screen and
monitor periodontal inflammation and to provide clues to disease
pathogenesis. While MMP-8 has been widely studied in this context
(Sorsa et al., 2016), the potential of other salivary markers to screen
and monitor periodontal inflammation are to date less studied. This
study found that salivary levels of the myeloid-related markers CSF-1,
S100A8/A9, S100A12, HGF, IL-1β, and MMP-8 were increased, while
IL-34 was decreased in periodontitis. IL-1β and MMP-8 levels
decreased significantly 1 month, whereas IL-34 increased 3 months
after therapy. Additionally, we found S100A8/A9 levels in saliva strat-
ified periodontitis patients into two clusters with distinct clinical and
inflammatory characteristics.
We found increased salivary levels of CSF-1, S100A8/A9, and
S100A12 in both gingivitis and periodontitis in comparison with
healthy participants. These markers also showed significant positive
correlations with clinical periodontal parameters. On the other hand,
IL-34 levels were significantly lower in periodontitis than in both
healthy and gingivitis, and correlated negatively to the percentage of
sites with PPD ≥5 mm. As both CSF-1 and IL-34 share a receptor,
CSF-1R, and their levels are differentially modulated in response to
periodontitis, we looked at their ratio and found it also to be higher in
periodontitis. These results are partially in agreement with previous
findings of altered levels of these markers in saliva in periodontal dis-
ease (Haririan et al., 2016; Lira-Junior, Akerman, et al., 2017; Martinez
et al., 2017; Lira-Junior et al., 2020) and add more evidence to the role
of myeloid cells in periodontal pathogenesis. In contrast to a previous
study from our group (Martinez et al., 2017), here we found that
CSF-1 and IL-34 levels were dysregulated in gingivitis in comparison
with health and periodontitis, respectively. We believe this could be
at least partially explained by the differences in the clinical
F IGURE 2 Effect of periodontal treatment on salivary levels of myeloid-related markers in periodontitis patients. Salivary levels of (a) Colony-
stimulating factor-1 (CSF-1), (b) interleukin-34 (IL)-34, (c) S100A8/A9, (d) S100A12, (e) hepatocyte growth factor (HGF), (f) IL-1β, and (g) matrix
metalloproteinase (MMP)-8 in periodontitis patients (n = 66) at baseline (M0) and 1 (M1), 3 (M3), and 6 months (M6) after non-surgical
periodontal treatment. Groups were compared using Friedman tests with Dunn's post hoc test. aSignificantly different in comparison with M0.
Data are presented as mean±standard error of mean
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inflammation between the cohorts, as the gingivitis group in the previ-
ous study had a mean BOP of 10% whereas the mean here was 28%.
It is noteworthy to report that these myeloid-related markers cor-
related significantly to the more well-known markers of periodontal
inflammation such as IL-1β and MMP-8 (Jaedicke et al., 2016). This is
in line with other studies pointing out that inflammatory cytokines
correlate to each other in saliva (Lira-Junior, Akerman, et al., 2017;
Martinez et al., 2017; Medara et al., 2020), forming an inflammatory
network. Since these markers are mainly expressed by myeloid cells, it
is possible that their levels reflect ongoing changes in these cells in tis-
sue during disease. Along with the correlation to myeloid-related
markers, HGF, IL-1β and MMP-8 also displayed higher levels in saliva
from both periodontitis and gingivitis than healthy participants. More-
over, similarly to S100A8/A9 and the CSF-1/IL-34 ratio, they were
also higher in periodontitis than in gingivitis. This is in concordance
with previous literature, which has consistently shown increased
levels of these markers in periodontitis (reviewed in Sorsa et al., 2016;
Jaedicke et al., 2016).
F IGURE 3 Salivary levels of myeloid-related markers according to baseline levels of S100A8/A9 and their modulation by periodontal
treatment. (a) Salivary levels of S100A8/A9 in periodontitis patients (n = 72) displaying two groups with distinct expression. (b) Colony-
stimulating factor-1 (CSF-1), (c) interleukin-34 (IL)-34, (d) S100A12, (e) hepatocyte growth factor (HGF), (f) IL-1β, and (g) matrix metalloproteinase
(MMP)-8 levels in periodontitis patients with low (n = 34) and high (n = 38) levels of S100A8/A9 at baseline. (h) S100A8/A9, (i) CSF-1, (j) IL-34,
(k) S100A12, (l) HGF, (m) IL-1β, and (n) MMP-8 at baseline (M0) and 1 (M1), 3 (M3), and 6 months (M6) after non-surgical periodontal treatment in
patients with low and high S100A8/A9 levels at baseline. Groups were compared using Mann–Whitney tests. *p < .05, **p < .001. Intra-group
comparisons were done with Friedman tests with Dunn's post hoc test. aSignificantly different in comparison with M0. Data are presented as
mean±standard error of mean [Colour figure can be viewed at wileyonlinelibrary.com]
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We also assessed the ability of these myeloid-related markers to
differentiate between the different periodontal conditions. While
most markers exhibited good ability to discriminate between peri-
odontitis and health, this ability decreased when analysing gingivitis
alone or in combination with health. This is expected, as some of
these markers also showed altered levels in gingivitis and had previ-
ously been appreciated for IL-1β and MMP-8, for example (Ebersole
et al., 2015). Despite that, CSF-1, IL-34, and the S100A proteins
exhibited moderate performance in distinguishing periodontitis
patients from gingivitis/healthy participants, with AUC varying from
0.67 to 0.74, whereas HGF, IL-1β, and MMP-8 performed well in dif-
ferentiating periodontitis from gingivitis/health. It is important to fully
validate these biomarkers and analyse their performance in differenti-
ating between the different periodontal conditions, as those that reli-
ably reflect the periodontal condition could be used, among others, in
settings where a full-mouth examination is not feasible or in large-
scale population screenings, after which individuals can be referred to
a dentist.
Furthermore, we assessed the effect of periodontal intervention
on the levels of these markers and found that IL-1β and MMP-8
decreased significantly at 1 month, while the CSF-1/IL-34 ratio
decreased at a later timepoint, that is, 3 months after periodontal
treatment. IL-34, on the other hand, increased significantly 3 months
post therapy. These results are partially in agreement with previous
studies demonstrating the effects of root surface debridement in
reducing the salivary levels of IL-1β, MMP-8 (Kinney et al., 2011;
Sexton et al., 2011), and CSF-1/IL-34 ratio in periodontitis (Martinez
et al., 2017). A previous small exploratory study, however, did not find
a significant effect of periodontal therapy on IL-34 levels (Martinez
et al., 2017). It is important to mention that we had reported a signifi-
cant decrease in MMP-8 levels 6 months after treatment (Taylor
et al., 2019), and now we extend this finding by showing that this
decrease happened 1 month after treatment and it was maintained
until the end of follow-up without further significant change.
We observed two distinct clusters of periodontitis patients based
on their levels of S100A8/A9, where patients with “high” levels
exhibited 13 times higher mean S100A8/A9 than patients with “low”
levels. These clusters presented different clinical and inflammatory
features, such as slightly younger age, more bleeding and inflamed
surface, deeper pockets, and increased S100A12 in patients with high
S100A8/A9. High variability in S100A8/A9 levels and patient cluster-
ing have been previously reported in gingival crevicular fluid
(Que et al., 2004; Farina et al., 2012) and saliva (Lira-Junior, Ozturk,
et al., 2017). Our previous study found participant clustering based on
the levels of S100A8/A9, where the group with “high S100A8/A9”
was older and showed increased levels of CSF-1, MMP-8, and macro-
phage migration inhibitory factor in saliva (Lira-Junior, Ozturk,
et al., 2017). However, this pattern observed in the previous study
included participants with different periodontal conditions, while in
the current study only periodontitis patients were included in the
analysis, which can account at least partially for the contradictory
results. This will need to be addressed in further studies of indepen-
dent patient cohorts.
Interestingly, S100A8/A9 levels followed opposite trends after
treatment in the two clusters of patients: decreasing in patients with
“high levels” at baseline, and increasing in those with “low levels”,
reaching similar levels 6 months after treatment. This was accompa-
nied by differences in the periodontal condition after treatment,
where patients with “high levels” had worse gingival inflammation
and greater epithelial surface area at the end of follow-up in compari-
son with those with “low levels”. Furthermore, HGF, IL-1β and MMP-
8 decreased significantly in patients with “low levels”. In concordance
with our findings, Que et al. (2004) found, in a study of experimental
gingivitis, that the amount of S100A8/A9 in GCF identified two
groups of participants with different response patterns. Additionally,
Kaner et al. (2011) reported elevated levels of S100A8/A9 in GCF in
sites that were found to progress, suggesting that it could be used to
predict disease activity. S100A8/A9 is mainly expressed by myeloid
cells and comprises approximately 45% of the cytosolic protein con-
tent in neutrophils (Edgeworth et al., 1991). Thus, given its short half-
life in circulation, it is tempting to speculate S100A8/A9 as a good
marker of ongoing inflammatory activity in the periodontal tissues.
However, whether the levels of S100A8/A9 indicate different suscep-
tibility profiles to periodontitis and are related to risk of future peri-
odontal breakdown deserve investigation.
Our findings should be interpreted in the context of the limita-
tions of the clinical study. This was an observational study in which
only periodontitis patients were monitored longitudinally. Randomized
clinical trials assessing the effect of periodontal treatment on the
levels of these biomarkers are warranted. Also, monitoring of both
periodontally healthy and gingivitis participants would have been of
great value to better understand the variations in biomarker concen-
trations and whether they can predict progression from gingivitis to
periodontitis. Longer follow-ups in larger cohorts are also necessary
to evaluate whether these markers can predict disease activity.
Further, an evaluation of the salivary microbial profile could increase
our understanding of the distinct S100A8/A9 groups and their
relationship to disease progression and response to treatment (Kinney
et al., 2011). As periodontitis stems from an intricate, dysregulated
interaction between the host response and the microbial challenge,
clinical studies assessing a wide range of markers reflecting different
pathogenic processes will be critical in identifying useful markers that
could be translated into clinical practice and improve periodontal care
(Kinney et al., 2011; Salminen et al., 2014). Nevertheless, some
strengths of our study should also be highlighted, such as the well-
characterized clinical groups, the exclusion of potential confounders,
and the blinded evaluation of the biomarkers. Likewise, the analysis of
markers related to myeloid cells is relevant given the critical role
of these cells in the pathogenesis of periodontitis.
In conclusion, the salivary levels of myeloid-related markers are
altered in periodontitis and could be used to distinguish periodontitis
from non-periodontitis patients. Treatment of periodontitis had a sig-
nificant impact on the levels of IL-34, IL-1β, MMP-8, and the CSF-1/
IL-34 ratio. Furthermore, we showed that measuring S100A8/A9 in
saliva could identify distinct groups of periodontitis patients with dif-
ferent clinical and inflammatory features at baseline and after
LIRA-JUNIOR ET AL. 9
treatment. Assessment of biomarkers in saliva is already a reality, and
gives insights into disease pathogenesis, stratification, and monitoring.
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